Trade secret litigation has always had a funny little paradox baked into it: the plaintiff must explain the secret well enough to sue over it, but not so well that the secret stops feeling very secret. In Quintara Biosciences, Inc. v. Ruifeng Biztech, Inc., the U.S. Court of Appeals for the Ninth Circuit stepped directly into that awkward legal dance and gave businesses, lawyers, and in-house teams a clearer answer under the Defend Trade Secrets Act, or DTSA.
The headline is important and practical: the Ninth Circuit held that the DTSA does not require a plaintiff to identify its alleged trade secrets with California-style particularity at the very start of discovery. That does not mean plaintiffs get a free pass to wave their hands and say, “Our trade secrets are, you know, all the smart stuff.” It means something more measured. Under federal law, the question of whether a trade secret has been described with sufficient particularity is usually a fact issue that develops through discovery and is typically sorted out at summary judgment or trial.
For companies litigating trade secret claims in California federal court, that distinction matters a lot. It changes pleading strategy. It changes discovery fights. It changes how plaintiffs and defendants think about the relationship between the DTSA and the California Uniform Trade Secrets Act, known as CUTSA. And it reminds everyone involved that trade secret litigation is not patent litigation in a borrowed trench coat.
What happened in the case?
The dispute involved Quintara Biosciences and Ruifeng Biztech, two California-based DNA-sequencing-analysis companies. According to the Ninth Circuit’s description of the record, the companies had a business relationship from 2013 to 2019. After that relationship fell apart, Quintara alleged that Ruifeng locked Quintara out of its office, took possession of equipment, and hired Quintara employees. Quintara then sued.
Here is the detail that shaped the appeal: Quintara brought a federal DTSA claim, but it did not bring a CUTSA claim. In its complaint, Quintara identified several categories of alleged trade secrets, including customer and vendor databases, a marketing plan, software code, customized reagents and protocols, designs for new products, and DNA Donor technology. That was enough to tee up the lawsuit, but not enough to satisfy the defendant, which wanted more specificity before turning over discovery.
Ruifeng pushed the district court to apply California Code of Civil Procedure section 2019.210, a CUTSA rule requiring a plaintiff to identify a trade secret with “reasonable particularity” before discovery relating to the trade secret begins. The district court leaned on that state-law concept and ordered Quintara to provide a more detailed disclosure, including something that looked suspiciously patent-like: a list of precise claimed trade secrets and their specific elements.
Quintara supplemented its disclosure under seal and added more technical detail. Ruifeng still said it was not enough. The district court then struck nine of the asserted trade secrets, effectively trimming the case down to two. One of those claims was later dropped, and a jury returned a verdict for Ruifeng on the remaining trade secret claim. Quintara appealed the order that struck the other trade secrets, and that appeal produced the Ninth Circuit ruling everyone in trade secret circles started underlining with great enthusiasm.
What exactly did the Ninth Circuit hold?
The Ninth Circuit reversed the district court’s order striking Quintara’s trade secrets. Its reasoning turned on a simple but powerful distinction: CUTSA’s “reasonable particularity” disclosure rule is not automatically imported into a federal DTSA-only case.
The court emphasized that the DTSA creates a federal cause of action for trade secret misappropriation, and the statute itself does not say that a plaintiff must identify trade secrets with particularity before discovery starts. Instead, the normal machinery of the Federal Rules of Civil Procedure applies. That means district courts still have broad tools to manage sensitive discovery, sequence disclosure, and protect confidential information. But those tools do not authorize a court to turn a state-law disclosure rule into a rigid federal gatekeeping device for a DTSA claim.
The Ninth Circuit also made clear that “sufficient particularity” still matters under the DTSA. A trade secret plaintiff cannot rely on vague catchall descriptions or broad categories forever. Eventually, the plaintiff must prove that the alleged secret is defined well enough to separate it from general knowledge in the trade and from the ordinary know-how of skilled people in the field. That is a real requirement. It is just not necessarily a day-one, patent-claim-style disclosure requirement.
In other words, the Ninth Circuit did not say, “Be vague, have fun, see you at trial.” It said that whether a trade secret has been identified with sufficient particularity is usually a factual question, one that often cannot be fairly resolved before at least some discovery occurs. That is a meaningful difference. It shifts the issue from a premature discovery roadblock to a merits question that may be refined through an iterative process.
The panel also rejected the use of Rule 12(f) as the basis for striking Quintara’s trade secrets. Rule 12(f) is for striking insufficient defenses or redundant, immaterial, impertinent, or scandalous matter. The court concluded Quintara’s trade secret disclosures did not fit that box. The panel then went further and held that using discovery-management authority under Rules 16 and 26 to effectively dismiss most of the claim was too harsh on the facts presented.
The opinion is especially notable for its practical tone. The court openly acknowledged the “delicate problem” at the heart of trade secret discovery: plaintiffs do not want to expose the very information they say was stolen, and defendants do not want to hand over their own proprietary material in response to a claim that has not yet been sharply defined. The court’s answer was not blunt-force dismissal. It was case management.
Why this ruling matters for DTSA litigation
This decision matters because it draws a sharper line between federal and California trade secret procedure. For years, litigants in California federal courts often argued over whether CUTSA’s pre-discovery disclosure rule should shape the handling of federal DTSA claims. The Ninth Circuit now says that in a DTSA-only case, the state rule does not control the federal claim.
That creates an obvious strategic consequence. Plaintiffs who have the option to plead both DTSA and CUTSA claims may now think harder about whether adding a CUTSA claim is worth the procedural baggage. Sometimes it will be. State claims can still matter for remedies, venue, or broader litigation strategy. But this ruling makes clear that if a plaintiff proceeds only under the DTSA, it is not automatically signing up for California’s early “reasonable particularity” disclosure regime.
For defendants, the case is not bad news so much as a change in tactics. The ruling does not shut down challenges to sloppy trade secret identifications. It simply says the challenge should usually be framed through smarter tools: protective orders, phased discovery, targeted motions, limits on the scope of confidential disclosures, and eventually summary judgment if the plaintiff still cannot define the alleged trade secrets in a legally meaningful way.
The opinion also helps clear up a common misunderstanding about trade secret pleading. Some people talk as though trade secret plaintiffs must choose between two impossible options: reveal the secret in full or lose the case. The Ninth Circuit took a more realistic view. Trade secret identification can evolve. Discovery may help a plaintiff refine what matters, what was allegedly taken, and how the claimed secret differs from public or industry-known information.
Still, the court was careful not to overreach. It did not say CUTSA’s section 2019.210 is irrelevant in every federal forum. It expressly noted that the appeal involved only a DTSA claim and did not decide whether the California disclosure rule is binding when a federal court is adjudicating an actual CUTSA claim. That nuance matters. Anyone reading the case as a universal license to dodge specificity should put the highlighter down and step away from the coffee.
DTSA versus CUTSA: same neighborhood, different house rules
The DTSA and CUTSA often travel together, but they are not twins. The DTSA is the federal trade secret statute. CUTSA is California’s state trade secret law. The DTSA expressly does not preempt state trade secret remedies, which is why many complaints include both federal and state claims. But as this case shows, parallel claims can come with different procedural expectations.
Under CUTSA, section 2019.210 requires a plaintiff to identify the trade secret with reasonable particularity before trade-secret discovery begins. The purpose is sensible: prevent fishing expeditions, give defendants fair notice, and help courts draw reasonable boundaries around confidential discovery. California courts have long treated that rule as an important early checkpoint.
Under the DTSA, by contrast, the statute defines what counts as a trade secret and what counts as misappropriation, but it does not prescribe a California-style pre-discovery disclosure timing rule. The Ninth Circuit leaned on that absence. Federal procedure governs the sequencing. District courts retain broad discretion, but they must use that discretion in a way that fits federal law and the realities of trade secret litigation.
That distinction may sound technical, but it can shape the entire life of a case. Early disclosure fights influence timing, leverage, settlement pressure, and how much confidential material each side must reveal before the record is fully developed. In that sense, the Quintara decision is not just about wording. It is about litigation architecture.
Examples of what the ruling means in practice
Example 1: Source code and technical workflows
Suppose a software company alleges that a former partner copied a proprietary workflow embedded in its platform. At the start of the case, the company may be able to identify the trade secret as a specific data-processing architecture, a nonpublic rule set, or a confidential code-based method without disclosing every line of source code in the complaint. After discovery, however, the plaintiff will still need to define the secret with enough detail to show it is not just ordinary coding practice wearing a fake mustache.
Example 2: Customer pricing and business intelligence
Imagine a company claims its nonpublic customer segmentation model, pricing tolerances, and renewal-risk formulas were taken by a competitor. A complaint that merely says “confidential customer information” is probably too mushy in the long run. But under the Ninth Circuit’s approach, the court may allow discovery to proceed in a controlled way so the plaintiff can refine the claim and the defendant can test whether the information was actually secret, valuable, and misappropriated.
Example 3: Scientific know-how and lab protocols
In biotech, the problem is even sharper because the trade secret may involve a blend of reagents, methods, testing parameters, negative know-how, and production choices. Early on, plaintiffs may be reluctant to put the secret on public display with patent-claim precision. The Ninth Circuit’s decision recognizes that concern. But again, the plaintiff eventually must do the hard work of distinguishing what is truly proprietary from what is standard science or generally known technique.
Key takeaways for businesses and lawyers
First, plaintiffs should treat the decision as breathing room, not a hall pass. The safer reading is this: you do not need to fully map the treasure chest on day one, but by the merits stage you still need a map, a compass, and a convincing explanation of why the treasure was actually yours.
Second, defendants should shift from all-or-nothing dismissal tactics toward precision tools. Protective orders, staged discovery, motions focused on narrowing the universe of alleged trade secrets, and later summary judgment attacks may all be more effective than trying to end the case before the record exists.
Third, companies should coordinate legal, technical, and business teams early. Trade secret cases often fail not because the information lacks value, but because the owner cannot clearly explain what the secret is, how it was protected, and why it was not generally known. Courts are not mind readers, and neither are juries.
Fourth, complaint strategy matters more than ever in California. The choice between asserting DTSA only, CUTSA only, or both is no longer just a routine drafting decision. It can affect disclosure timing, discovery burdens, and the shape of the fight.
Real-world experiences and lessons from disputes like this
In practice, cases like this often feel less like tidy legal theory and more like controlled chaos with a confidentiality stamp on it. One common experience is that a business comes into court convinced the theft is obvious, while its legal team quickly realizes that obvious inside the company is not the same as legally identifiable outside the company. Engineers may say, “They took our platform logic,” scientists may say, “They copied our process,” and executives may say, “They stole the whole playbook.” A court, however, wants something tighter than collective outrage.
Another familiar experience is the early tension between speed and precision. A company that believes a former partner, employee, or competitor moved fast with confidential information usually wants immediate relief. It wants discovery now, injunction briefing now, maybe a laptop image yesterday. But technical teams are often still sorting through versions, repositories, notebooks, CRM exports, or lab records to figure out exactly what information was unique, who had access to it, and what was truly secret as opposed to merely useful. That lag creates the same problem the Ninth Circuit recognized: pushing for extreme specificity too early can be unrealistic and even dangerous.
On the defense side, the experience is different but just as frustrating. Defendants often feel they are being accused of stealing “everything and nothing” at the same time. They see broad labels like customer strategy, business methods, code, formulas, know-how, and product design and reasonably ask what, exactly, they are supposed to defend against. Without boundaries, discovery can look like an expensive fishing expedition with better suits. That is why protective orders, phased disclosure, and careful case management matter so much in trade secret disputes.
There is also a practical lesson that shows up again and again: companies that consistently document confidentiality measures usually tell a cleaner story in court. Access controls, confidentiality agreements, need-to-know limits, repository restrictions, clean offboarding, and disciplined internal labeling do not just reduce theft risk. They help transform a messy business grievance into a legally coherent trade secret claim. When those safeguards are weak, parties often spend half the case arguing over whether the alleged secret was actually treated as secret at all.
Finally, many trade secret fights reveal a communication gap inside companies. The legal issue is not only whether a trade secret exists, but whether business and technical stakeholders can describe it in a way a judge can use. The companies that do this best usually avoid both extremes. They do not disclose the family recipe to the whole internet, but they also do not show up saying, “Trust us, it was extremely proprietary.” The Quintara ruling fits that real-world experience. It acknowledges that specificity is essential, just not always fully available at the opening bell.
Conclusion
The Ninth Circuit’s ruling in Quintara Biosciences is a significant development for trade secret litigation under the DTSA. The court did not lower the ultimate bar for proving a trade secret. Plaintiffs still must identify their alleged secrets with sufficient particularity, prove they were actually secret, show they had independent economic value, and connect the dots to misappropriation. What the court rejected was the idea that federal DTSA claims automatically inherit California’s pre-discovery disclosure timing rule.
That makes the decision both narrower and more useful than a flashy headline suggests. It narrows premature dismissal in DTSA-only cases, but it also gives district courts a roadmap for managing discovery without wrecking the merits before they are ready. For plaintiffs, that means room to refine. For defendants, that means better tools than a blunt motion to strike. And for anyone litigating trade secret claims in the Ninth Circuit, it means one thing above all: trade secret identification is still essential, but under the DTSA it is usually a process, not a starting gun.
